Pal A, Shinde R, Miralles M, Workman P, de Bono J
Nat Rev Clin Oncol. 2021; 18(7):454-467.
PMID: 33762744
DOI: 10.1038/s41571-021-00489-x.
Park J, Im H, Hong S, Castro C, Weissleder R, Lee H
ACS Photonics. 2018; 5(2):487-494.
PMID: 29805987
PMC: 5966285.
DOI: 10.1021/acsphotonics.7b00992.
Lin T, Guo W, Long Q, Ma A, Liu Q, Zhang H
Theranostics. 2016; 6(9):1324-35.
PMID: 27375782
PMC: 4924502.
DOI: 10.7150/thno.14882.
Webber P, Park C, Qui M, Ramalingam S, Khuri F, Fu H
Oncoscience. 2015; 2(9):765-776.
PMID: 26501082
PMC: 4606010.
DOI: 10.18632/oncoscience.245.
Butler L, Ferraldeschi R, Armstrong H, Centenera M, Workman P
Mol Cancer Res. 2015; 13(11):1445-51.
PMID: 26219697
PMC: 4645455.
DOI: 10.1158/1541-7786.MCR-15-0234.
Selective targeting of the stress chaperome as a therapeutic strategy.
Taldone T, Ochiana S, Patel P, Chiosis G
Trends Pharmacol Sci. 2014; 35(11):592-603.
PMID: 25262919
PMC: 4254259.
DOI: 10.1016/j.tips.2014.09.001.
Translation of anticancer efficacy from nonclinical models to the clinic.
Stroh M, Duda D, Takimoto C, Yamazaki S, Vicini P
CPT Pharmacometrics Syst Pharmacol. 2014; 3:e128.
PMID: 25098530
PMC: 4150926.
DOI: 10.1038/psp.2014.28.
Ascorbic acid inhibition of Candida albicans Hsp90-mediated morphogenesis occurs via the transcriptional regulator Upc2.
Van Hauwenhuyse F, Fiori A, Van Dijck P
Eukaryot Cell. 2014; 13(10):1278-89.
PMID: 25084864
PMC: 4187652.
DOI: 10.1128/EC.00096-14.
Appraising iniparib, the PARP inhibitor that never was--what must we learn?.
Mateo J, Ong M, Tan D, Gonzalez M, de Bono J
Nat Rev Clin Oncol. 2013; 10(12):688-96.
PMID: 24129347
DOI: 10.1038/nrclinonc.2013.177.
HSP90: chaperone-me-not.
Patki J, Pawar S
Pathol Oncol Res. 2013; 19(4):631-40.
PMID: 23900891
DOI: 10.1007/s12253-013-9675-4.
Molecular chaperone therapy- the future in cancer.
Shehzad A, Dawani O, Munir S, Hussain S
Infect Agent Cancer. 2012; 7(1):20.
PMID: 22889181
PMC: 3490745.
DOI: 10.1186/1750-9378-7-20.
Discovery of small molecule cancer drugs: successes, challenges and opportunities.
Hoelder S, Clarke P, Workman P
Mol Oncol. 2012; 6(2):155-76.
PMID: 22440008
PMC: 3476506.
DOI: 10.1016/j.molonc.2012.02.004.
Novel C-terminal Hsp90 inhibitor for head and neck squamous cell cancer (HNSCC) with in vivo efficacy and improved toxicity profiles compared with standard agents.
Cohen S, Mukerji R, Samadi A, Zhang X, Zhao H, Blagg B
Ann Surg Oncol. 2011; 19 Suppl 3:S483-90.
PMID: 21837531
PMC: 5828498.
DOI: 10.1245/s10434-011-1971-1.
A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors.
Pacey S, Wilson R, Walton M, Eatock M, Hardcastle A, Zetterlund A
Clin Cancer Res. 2011; 17(6):1561-70.
PMID: 21278242
PMC: 3060938.
DOI: 10.1158/1078-0432.CCR-10-1927.
Preclinical pharmacology, antitumor activity, and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930.
Yap T, Walton M, Hunter L, Valenti M, Brandon A, Eve P
Mol Cancer Ther. 2010; 10(2):360-71.
PMID: 21191045
PMC: 4944842.
DOI: 10.1158/1535-7163.MCT-10-0760.
A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma.
Pacey S, Gore M, Chao D, Banerji U, Larkin J, Sarker S
Invest New Drugs. 2010; 30(1):341-9.
PMID: 20683637
DOI: 10.1007/s10637-010-9493-4.
Hsp90 inhibition: elimination of shock and stress.
Duerfeldt A, Blagg B
Bioorg Med Chem Lett. 2010; 20(17):4983-7.
PMID: 20656483
PMC: 3166208.
DOI: 10.1016/j.bmcl.2010.06.108.
Envisioning the future of early anticancer drug development.
Yap T, Sandhu S, Workman P, de Bono J
Nat Rev Cancer. 2010; 10(7):514-23.
PMID: 20535131
DOI: 10.1038/nrc2870.
Drugging the PI3 kinome: from chemical tools to drugs in the clinic.
Workman P, Clarke P, Raynaud F, van Montfort R
Cancer Res. 2010; 70(6):2146-57.
PMID: 20179189
PMC: 3242038.
DOI: 10.1158/0008-5472.CAN-09-4355.
Proton MRS detects metabolic changes in hormone sensitive and resistant human prostate cancer models CWR22 and CWR22r.
Le H, Lupu M, Kotedia K, Rosen N, Solit D, Koutcher J
Magn Reson Med. 2009; 62(5):1112-9.
PMID: 19780165
PMC: 2859036.
DOI: 10.1002/mrm.22137.
